Celik Muhammet, Gold Mark S, Fuehrlein Brian
New York Medical College at Saint Joseph's Medical Center, Yonkers, NY 10705, USA.
Department of Psychiatry, School of Medicine, Washington University, St. Louis, MO 63130, USA.
Brain Sci. 2024 Mar 20;14(3):294. doi: 10.3390/brainsci14030294.
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies. While these advancements show potential, further research is crucial for a comprehensive understanding of their effectiveness. The clear shortage of approved medications and other treatment modalities underscores the pressing need for ongoing research.
酒精使用障碍(AUD)是美国发病和死亡的一个重要因素。它每年导致超过140,000人死亡,在全球范围内导致超过200种相关疾病和健康状况,占全球疾病负担的5.1%。尽管其影响巨大,但AUD的治疗仍不充分,其特点是获批药物稀缺。本文探讨了酒精戒断综合征和AUD的当前治疗情况及新策略。最近的研究取得了一些有前景的成果,包括将迷幻剂与心理治疗相结合、基于非侵入性神经回路的干预措施、磷酸二酯酶-4抑制剂和胰高血糖素样肽-1受体激动剂。虽然这些进展显示出潜力,但进一步的研究对于全面了解其有效性至关重要。获批药物和其他治疗方式的明显短缺凸显了持续研究的迫切需求。
Am J Psychiatry. 2023-8-1
Alcohol. 2024-12
J Clin Exp Hepatol. 2023
Complex Psychiatry. 2025-3-3
Risk Manag Healthc Policy. 2025-1-18
Clin Pract Epidemiol Ment Health. 2024-6-5
Cell Commun Signal. 2024-5-1
Cochrane Database Syst Rev. 2023-12-12
Biol Psychiatry Glob Open Sci. 2022-3-15
Fortschr Neurol Psychiatr. 2025-1